These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 26409664)

  • 21. [The frontline of TMA management].
    Saito K; Matsumoto M
    Rinsho Ketsueki; 2022; 63(5):463-470. PubMed ID: 35662172
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A mechanistic approach to the diagnosis and management of atypical hemolytic uremic syndrome.
    Tsai HM
    Transfus Med Rev; 2014 Oct; 28(4):187-97. PubMed ID: 25280590
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic approach to microangiopathic hemolytic disorders.
    Kottke-Marchant K
    Int J Lab Hematol; 2017 May; 39 Suppl 1():69-75. PubMed ID: 28447417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inherited thrombotic thrombocytopenic purpura mimicking immune thrombocytopenic purpura during pregnancy: a case report.
    Romão de Souza V; Beatriz Cavalcante de Oliveira A; Maria Vanderlei A; Queiroz da Mota Silveira Aroucha A; Pontes Duarte B; Nunes Machado A; Netto Chaer L; Wanderley de Barros Correia C; da Conceição de Barros Correia M; Freire Hazin Costa M
    J Med Case Rep; 2018 Jan; 12(1):15. PubMed ID: 29357939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.
    Furlan M
    Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):243-55. PubMed ID: 15030284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura.
    Zheng XL
    Annu Rev Med; 2015; 66():211-25. PubMed ID: 25587650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dissociation between the level of von Willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura.
    Snider CE; Moore JC; Warkentin TE; Finch CN; Hayward CP; Kelton JG
    Am J Hematol; 2004 Dec; 77(4):387-90. PubMed ID: 15551280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura.
    Tsai HM
    J Am Soc Nephrol; 2003 Apr; 14(4):1072-81. PubMed ID: 12660343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
    Furlan M; Lämmle B
    Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome.
    Cataland SR; Wu HM
    Blood; 2014 Apr; 123(16):2478-84. PubMed ID: 24599547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Complement activation in diseases presenting with thrombotic microangiopathy.
    Meri S
    Eur J Intern Med; 2013 Sep; 24(6):496-502. PubMed ID: 23743117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential for Recombinant ADAMTS13 as an Effective Therapy for Acquired Thrombotic Thrombocytopenic Purpura.
    Tersteeg C; Schiviz A; De Meyer SF; Plaimauer B; Scheiflinger F; Rottensteiner H; Vanhoorelbeke K
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2336-42. PubMed ID: 26338302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hereditary hemolytic uremic syndromes and thrombotic thrombocytopenic purpura].
    Loirat C; Sellier-Leclerc AL; Frémeaux-Bacchi V; Dragon-Durey A; Girma JP; Veyradier A
    Nephrol Ther; 2006 Jan; 2 Suppl 2():S149-61. PubMed ID: 17373216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies.
    Vigna E; Petrungaro A; Perri A; Terzi D; Recchia AG; Mendicino F; La Russa A; Bossio S; De Stefano L; Zinno F; Bonofiglio R; Morabito F; Gentile M
    Transfus Apher Sci; 2018 Apr; 57(2):247-249. PubMed ID: 29567368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STEC-HUS, atypical HUS and TTP are all diseases of complement activation.
    Noris M; Mescia F; Remuzzi G
    Nat Rev Nephrol; 2012 Nov; 8(11):622-33. PubMed ID: 22986360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of ADAMTS-13 activity and complement mutational analysis in differentiating acute thrombotic microangiopathies.
    Phillips EH; Westwood JP; Brocklebank V; Wong EK; Tellez JO; Marchbank KJ; McGuckin S; Gale DP; Connolly J; Goodship TH; Kavanagh D; Scully MA
    J Thromb Haemost; 2016 Jan; 14(1):175-85. PubMed ID: 26559391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanisms in thrombotic thrombocytopenic purpura.
    Tsai HM
    Semin Thromb Hemost; 2004 Oct; 30(5):549-57. PubMed ID: 15497097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel CD46 mutation in a patient with microangiopathy clinically resembling thrombotic thrombocytopenic purpura and normal ADAMTS13 activity.
    Rossio R; Lotta LA; Pontiggia S; Borsa NG; Garagiola I; Ardissino G; Mikovic D; Cugno M; Peyvandi F
    Haematologica; 2015 Mar; 100(3):e87-9. PubMed ID: 25381125
    [No Abstract]   [Full Text] [Related]  

  • 39. Natural history of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
    Wada H; Matsumoto T; Yamashita Y
    Semin Thromb Hemost; 2014 Nov; 40(8):866-73. PubMed ID: 25377323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis.
    Laurence J
    Clin Adv Hematol Oncol; 2012 Oct; 10(10 Suppl 17):1-12. PubMed ID: 23187605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.